OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Oncology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?	59
Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy	41
Collecting information from all sarcoma reference cancer centres worldwide: achievement and next steps	38
Role of PSMA PET/CT in imaging and management of prostate cancer	32
Progress in diagnosis and treatment of checkpoint inhibitor pneumonitis	30
Neurorehabilitation in brain tumours: evidences and suggestions for spreading of knowledge and research implementation	28
Content features and its implementation in novel app-based psycho-oncological interventions for cancer survivors: a narrative review	26
Treatments and challenges in advanced prostate cancer	23
Harnessing dendritic cells for innovative therapeutic cancer vaccines	23
The role of signaling lymphocyte activation molecule family receptors in hematologic malignancies	21
Editorial introductions	20
State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies	19
First and further-line multidisciplinary treatment of retroperitoneal sarcomas	18
Epigenetic dynamics of aging and cancer development: current concepts from studies mapping aging and cancer epigenomes	18
Psycho-oncology interventions focusing on fatigue and sleep disturbances	17
Importance of guidelines and networking for the management of rare gynecological cancers	16
State-of-the-art and trends in fibroblast growth factor receptor-directed therapies in gastro-intestinal malignancies	16
Editorial introductions	16
Biomarkers and immunotherapy: where are we?	15
Safety of assisted reproductive techniques in gynecological cancer patients	15
Editorial introductions	15
Can we yet use tertiary lymphoid structures as predictive biomarkers for immunotherapy response in melanoma?	14
Impact of sentinel node use in lymphedema formation among gynecologic cancer patients	13
New hopes in relapsed refractory primary central nervous system lymphoma	13
Neoadjuvant and adjuvant approaches in gastroesophageal cancers	12

How to prevent human papillomavirus-related oropharyngeal cancer?	12
Local treatment in patients with hereditary breast cancer: decision-making process in low-, moderate-, high-penetrance pathogenic germline mutation carriers	12
Beyond ‘the good, the bad and the ugly’: let us put rectal cancer patients at the centre of the decision making	12
Melanoma with genetic alterations beyond the BRAF V600 mutation: management and new insights	11
Enhancing proactive life-sustaining treatment preference documentation in advanced cancer care: barriers and recommendations	11
Recent advances in precision medicine for acute myeloid leukemia	11
WHO 2021 and beyond: new types, molecular markers and tools for brain tumor classification	11
A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately?	11
Circulating tumor DNA in breast cancer: a biomarker for patient selection	11
Pregnancy-related hormonal changes and thyroid growth: do they have an impact on the higher incidence of differentiated thyroid cancer in women?	11
Lung cancer screening in never smokers	10
Editorial introductions	10
State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies	10
Liquid biopsy in brain tumors: moving on, slowly	10
Immunomodulation for hepatocellular carcinoma therapy: current challenges	10
Dyadic psychosocial interventions for patients with cancer and their caregivers: an update	10
Controversies in central nervous system prophylaxis of high-risk diffuse large B-cell lymphoma	10
Editorial introductions	9
Interventions aiming to improve advance care planning uptake in oncology: a scoping review of recent randomized controlled trials	9
Current evidence of integrative oncology modalities for managing adverse effects and survivorship issues among adolescents and young adult (AYA) cancer patients and survivors	9
Antibody–drug conjugates in rare genitourinary tumors: review and perspectives	9
Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results	9
Pathology and new insights in central nervous system lymphomas	9
Editorial: Lung cancer: continuous progress in diagnosis and treatment	9
Machine learning applications and challenges in graft-versus-host disease: a scoping review	9
New developments in rare vulvar and vaginal cancers	9
Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations	8
Editorial introductions	8
Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up	8
The role of genetic testing in prostate cancer screening, diagnosis, and treatment	8
Antibodies targeting Prostate-Specific Membrane Antigen positive prostate cancer: from diagnostic imaging to theranostics	8
Desmoid tumors: who, when and how to treat?	8
Hybrid magnetic resonance and PET imaging for prostate cancer recurrence	8
Potential application of artificial intelligence in cancer therapy	7
Editorial introductions	7
The 5T's of health disparities in multiple myeloma in Latin America	7
A new comprehensive and stratified concept for supportive care in cancer patients	7
Advantages of robotic surgery in obese patients with endometrial cancer	7
Editorial introductions	7
Less is more in endometrial cancer (SLN, conservative treatment, radical hysterectomy, molecular classification)	7
State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies	7
Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients	7
The changing landscape for patients with relapsed/refractory acute myeloid leukaemia	7
The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy	7
Editorial introductions	7
Mind the target: programmed death ligand 1 in oesophagogastric cancers	7
How to become a Multinational Association of Supportive Care in Cancer-designated center of excellence in supportive care in cancer	7
How to support parenting in patients with cancer and co-parents? From research to practice	7
Preclinical glioma models in neuro-oncology: enhancing translational research	7
Targeting SUMOylation in cancer	6

Editorial introductions	6
Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer	6
Sarcoma incidence worldwide: regional differences in histology and molecular subtypes	6
Treatment of radiation-associated angiosarcoma	6
Pathologic diagnosis of lung cancer – recent developments	6
Controversies on chemotherapy for early HR+/HER2− breast cancer: the role of anthracyclines and dose intensification	6
Breast surgery after neoadjuvant therapy	6
Advances in the pathogenesis of FLT3-mutated acute myeloid leukemia and targeted treatments	6
Question prompt lists to improve communication between cancer patients and healthcare professionals	6
Editorial introductions	6
Adjuvant and neoadjuvant approaches in pancreatic cancer	6
Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results	6
Targeting cancer stem cell pathways for lung cancer therapy	6
When do I ask for a DNA methylation array for primary brain tumor diagnosis?	6
HER2-positive breast cancer: cotargeting to overcome treatment resistance	6
Immunotherapies in non-metastatic gastrointestinal cancers	6
Preoperative immunotherapy for head and neck cancers: state of art	5
How to monitor the side effects of treatments in cancer patients	5
Neoadjuvant immune checkpoint blockade enhances local and systemic tumor immunity in head and neck cancer	5
Clinical management of brain tumors in pregnancy	5
How to treat localized Hodgkin lymphoma?	5
Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas	5
Surgical treatment for clinical early-stage expansile and infiltrative mucinous ovarian cancer: can staging surgeries safely be omitted?	5
Molecular oncology: what is needed to speed access to innovative therapies in clinical research?	5
Polyamine metabolism in prostate cancer	5
Cellular therapies in sarcoma and other solid tumors	5
Current status of phosphoinotiside-3 kinase inhibitors in blood cancers	5
Thymic malignancies: role of immunotherapy and novel approaches	5
Are epigenetic-targeting approaches ready for prime time in neuroendocrine neoplasms?	5
Update on bi-specific monoclonal antibodies for blood cancers	5
Modeling the management of patients with human epidermal growth factor receptor 2-positive breast cancer with liquid biopsy: the future of precision medicine	5
Achievements of international rare cancers networks and consortia in the neuro-oncology field	5
HIV-related lymphomas	5
Therapeutic cancer vaccination against telomerase: clinical developments in melanoma	5
Recent advances in immunotherapy for small cell lung cancer	5
Immunotherapy of sarcomas with modified T cells	5